Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress
The details of the presentation are as follows:
- Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
-
Date and Time:
Thursday, October 29, 2020 , 3:00 –3:15 pm Central European Time - Session: D1T03.3C: Late-Breaking News Session
- Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/
About CTP-543 and Alopecia Areata
CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The
Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.
The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in
About Concert
1 Benigno M. Clinical, Cosmetic and Investigational Dermatology 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005078/en/
(781) 674-5284
ir@concertpharma.com
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com
Source: